ZA202405173B - Use of anti-idiopathic pulmonary fibrosis drug nintedanib in treatment of tuberculosis - Google Patents

Use of anti-idiopathic pulmonary fibrosis drug nintedanib in treatment of tuberculosis

Info

Publication number
ZA202405173B
ZA202405173B ZA2024/05173A ZA202405173A ZA202405173B ZA 202405173 B ZA202405173 B ZA 202405173B ZA 2024/05173 A ZA2024/05173 A ZA 2024/05173A ZA 202405173 A ZA202405173 A ZA 202405173A ZA 202405173 B ZA202405173 B ZA 202405173B
Authority
ZA
South Africa
Prior art keywords
tuberculosis
nintedanib
treatment
pulmonary fibrosis
idiopathic pulmonary
Prior art date
Application number
ZA2024/05173A
Other languages
English (en)
Inventor
Yu Lu
Xiaoyou Chen
Xueting Qi
Luyao Zheng
Lei Fu
Weiyan Zhang
Ning Wang
Original Assignee
Beijing Chest Hospital Capital Medical Univ
Beijing Tuberculosis Chest Cancer Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Chest Hospital Capital Medical Univ, Beijing Tuberculosis Chest Cancer Inst filed Critical Beijing Chest Hospital Capital Medical Univ
Publication of ZA202405173B publication Critical patent/ZA202405173B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2024/05173A 2022-04-29 2024-07-02 Use of anti-idiopathic pulmonary fibrosis drug nintedanib in treatment of tuberculosis ZA202405173B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210463752.6A CN114732818B (zh) 2022-04-29 2022-04-29 一种抗特发性肺纤维化药物尼达尼布在结核病治疗中的应用
PCT/CN2023/081772 WO2023207398A1 (zh) 2022-04-29 2023-03-16 一种抗特发性肺纤维化药物尼达尼布在结核病治疗中的应用

Publications (1)

Publication Number Publication Date
ZA202405173B true ZA202405173B (en) 2024-07-31

Family

ID=82285173

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2024/05173A ZA202405173B (en) 2022-04-29 2024-07-02 Use of anti-idiopathic pulmonary fibrosis drug nintedanib in treatment of tuberculosis

Country Status (5)

Country Link
US (1) US20250099458A1 (https=)
JP (1) JP7844766B2 (https=)
CN (1) CN114732818B (https=)
WO (1) WO2023207398A1 (https=)
ZA (1) ZA202405173B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114732818B (zh) * 2022-04-29 2023-02-10 首都医科大学附属北京胸科医院 一种抗特发性肺纤维化药物尼达尼布在结核病治疗中的应用
CN115645405B (zh) * 2022-11-10 2023-11-21 南方医科大学 顺苯磺酸阿曲库铵在制备抗结核抗生素增效剂中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1857725A (zh) * 2006-04-11 2006-11-08 济南帅华医药科技有限公司 一种含增效剂的复方抗结核药物缓释制剂
EP2311457A1 (en) * 2009-10-19 2011-04-20 Forschungszentrum Borstel Pharmaceutical compositions for treating infections with drug resistant mycobacteria
WO2015107482A1 (en) * 2014-01-17 2015-07-23 Piramal Enterprises Limited Pharmaceutical combination for treatment of tuberculosis
DK3377064T3 (da) * 2016-01-08 2019-09-23 Nerre Therapeutics Ltd Orvepitant til behandling af kronisk hoste
CN107019697A (zh) * 2016-02-02 2017-08-08 瑞阳(苏州)生物科技有限公司 预防或治疗纤维化疾病的药物组合物及其应用
GB201607865D0 (en) * 2016-05-05 2016-06-22 Ucl Business Plc Anti-tuberculous polymersomes
CN105902507A (zh) * 2016-06-12 2016-08-31 佛山市腾瑞医药科技有限公司 一种乙磺酸尼达尼布制剂及其应用
CN114732818B (zh) * 2022-04-29 2023-02-10 首都医科大学附属北京胸科医院 一种抗特发性肺纤维化药物尼达尼布在结核病治疗中的应用

Also Published As

Publication number Publication date
JP2025508098A (ja) 2025-03-21
JP7844766B2 (ja) 2026-04-14
US20250099458A1 (en) 2025-03-27
CN114732818A (zh) 2022-07-12
WO2023207398A1 (zh) 2023-11-02
CN114732818B (zh) 2023-02-10

Similar Documents

Publication Publication Date Title
ZA202405173B (en) Use of anti-idiopathic pulmonary fibrosis drug nintedanib in treatment of tuberculosis
JP2023011857A5 (https=)
Du et al. Fluorine in the pharmaceutical industry: FDA‐approved fluorine‐containing drugs in 2024
JP2024532374A5 (https=)
CN1976704B (zh) 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途
MX2020011653A (es) Métodos de tratamiento para el abuso de sustancias.
JP2020503247A5 (https=)
MY206521A (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
JP2017535561A5 (https=)
PH12020551597A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX2011002348A (es) Terapia de combinacion para tuberculosis.
JP2007506680A5 (https=)
EP2311457A1 (en) Pharmaceutical compositions for treating infections with drug resistant mycobacteria
JP2016523935A5 (https=)
Iseman Management of multidrug-resistant tuberculosis
FI4121058T3 (fi) Oksatsolidinoniyhdiste ja sen käyttö antibakteerisena aineena
RU2011104223A (ru) Азотсодержащее ароматическое гетероциклическое соединение
JP2016512507A5 (https=)
JP2020529440A5 (https=)
SI3113778T1 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
JP2020535172A5 (https=)
RU2017107715A (ru) Производные имидазо[1,2-a]пиридина для применения в качестве ингибиторов репликации вируса иммунодефицита человека
WO2015126930A2 (en) Booster drug therapy for mycobacterium infections
MX2023002522A (es) Compuestos novedosos para usar en el tratamiento de enfermedades asociadas con la angiotensina ii.
AU2020316449A8 (en) The peptidomimetic compound (R)-2-amino-N-((S)-L-(((S)-5-amino-L-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-l-oxopropan-2-yl)-5-guanidinopentanamide in the treatment of neurodegenerative diseases